"Trying to wrap my head around the potential re-administration of AAV with chimeric AAV"
Rethink the question..
Basically you are asking if a human is injected with a completely new engineered virus, how will the body respond.
We dont know until its actually injected in a human to test T cell response.
Ex vivo testing only tests for B cell response.
And mice and NHP respond differently to these viruses as well.
That is the problem.
And Solid Biosciences and ONCE are seeing this problem first hand.
But yes, people will need to try to improve specificity of targeting and efficacy of new modified viral vectors. ( Including SGMO)